PMC:7267243 / 20-30 JSON TXT

COVID‐19 associated pulmonary aspergillosis KOEHLER et al Abstract Summary Objectives Patients with acute respiratory distress syndrome (ARDS) due to viral infection are at risk for secondary complications like invasive aspergillosis. Our study evaluates coronavirus disease 19 (COVID‐19) associated invasive aspergillosis at a single centre in Cologne, Germany. Methods A retrospective chart review of all patients with COVID‐19 associated ARDS admitted to the medical or surgical intensive care unit at the University Hospital of Cologne, Cologne, Germany. Results COVID‐19 associated invasive pulmonary aspergillosis was found in five of 19 consecutive critically ill patients with moderate to severe ARDS. Conclusion Clinicians caring for patients with ARDS due to COVID‐19 should consider invasive pulmonary aspergillosis and subject respiratory samples to comprehensive analysis to detect co‐infection. 1 INTRODUCTION Since December 2019 coronavirus disease 2019 (COVID‐19) emerged from Wuhan City, Hubei province, China and rapidly spread around the globe becoming a pandemic threat. 1 Risk factors for invasive pulmonary aspergillosis (IPA) are well defined in immunocompromised populations. However, patients with acute respiratory distress syndrome (ARDS) due to viral infection are prone to secondary complications like invasive aspergillosis despite lack of underlying well‐defined immunocompromising disease. 2 , 3 , 4 Possible explanations for this could be an immune‐paralysis caused by viral infection‐induced ARDS and hypoxia compromising the innate host defence. 5 In light of influenza‐pulmonary associated aspergillosis, we retrospectively analysed our patients with COVID‐19 associated ARDS in the intensive care unit (ICU) at a single centre. 2 PATIENTS AND METHODS We performed a retrospective chart review of patients with COVID‐19 and ARDS admitted to the medical and surgical ICU at the University Hospital of Cologne, a 1540‐bed teaching hospital between 7 March 2020 and 22 April 2020 (Table 1). TABLE 1 Patient characteristics of patients with COVID‐19 associated invasive pulmonary aspergillosis Characteristics Patient #1 Patient #2 Patient #3 Patient #4 Patient #5 Gender Female Male Male Male Female Age (y) 62 70 54 73 54 Medical history Lap. cholecystectomy for cholecystitis Arterial hypertension Obesity with sleep apnea (BMI 31.5) Hypercholesterolemia Ex‐smoker (30 PY; 5 y previously) Moderate COPD (GOLD 2) Vertebral disc prolapse left L4/5, flavectomy and nucleotomy Ex‐smoker (4 months previously) Arterial hypertension Diabetes mellitus Aneurysm coiling right A. vertebralis Arterial hypertension Bullous Emphysema Smoker Severe COPD (GOLD 3) Previous Hepatitis B No Underlying immuno‐compromising condition (inhalational steroids for COPD) No (intravenous corticosteroid therapy 0.4 mg/kg/d, total of 13 d) (inhalational steroids for COPD) No ICU Ward MICU MICU SICU SICU MICU ARDS Horowitz‐Index, admission 12 Severe (53 mm Hg) Severe (93 mm Hg) Moderate (128 mm Hg) Severe (83 mm Hg) Moderate (167 mm Hg) Prone positioning Yes Yes Yes Yes Yes vvECMO Yes No No No No Acute renal failure Yes Yes Yes Yes Yes Dialysis No SLEDD SLEDD SLEDD No Microbiology Serum GM (>0.5) Negative Positive (0.7) Negative Negative 2× positive (2.7 and 1.3) Fungal culture BALF: Aspergillus fumigatus BALF: negative TA: Aspergillus fumigatus TA: Aspergillus fumigatus TA: negative Susceptibility testing Azole susceptible a Not applicable Azole susceptible Itraconazole MIC 0.380 (mg/L) Voriconazole MIC 0.094 (mg/L) Azole susceptible Itraconazole MIC 0.380 (mg/L) Voriconazole MIC 0.094 (mg/L) Not applicable Fungal PCR BALF: Aspergillus fumigatus BALF: Aspergillus fumigatus BALF: Aspergillus fumigatus TA: Aspergillus fumigatus TA: negative TA/BALF GM (>0.5) BALF: Positive (>2.5) BALF: Positive (>2.5) BALF: Positive (>2.5) Not available Not available Definition of IPA EORTC/MSG Criteria 8 Not classifiable (no host criterion) Not classifiable (no host criterion) Not classifiable (no host criterion) Not classifiable (no host criterion) Not classifiable (no host criterion) (modified) AspICU algorithm 3 , 7 Putative Modified putative 3 (GM positivity) Putative Putative Modified putative 3 (GM positivity) Virology PCR TA: positive for hMPV and SARS‐CoV‐2 (E‐gene: C t 13.29; S‐gene: C t 12.61) TA: positive for hMPV and SARS‐CoV‐2(E‐gene: C t 34.29; ORF1 a/b: C t 31.47) TA positive for SARS‐CoV‐2 (E‐gene: C t 29.74; ORF1 a/b: C t 27.86) TA positive for SARS‐CoV‐2 (E‐gene: C t 21.47; ORF1 a/b: C t 20.12) TA positive for SARS‐CoV‐2 (C t values not available) CT imaging studies Combined bilateral ground‐glass opacities with crazy paving and peripheral nodular consolidations (Video S1, Figure 1A) Ground‐glass opacities with occasional nodules (Video S2, Figure 1B) Bilateral ground‐glass opacities, nodular infiltrates with cavities and air crescent sign (Video S3, Figure 1C) Ground‐glass opacities with occasional nodules, known bullous emphysema (Video S4, Figure 1D) Ground‐glass opacities, smaller areas with crazy paving pattern, central and peripheral consolidations, and smaller nodular infiltrates (Video S5, Figure 1E) Therapy Antifungal treatment Voriconazole iv (6/4 mg/kg BW twice daily) Isavuconazole iv (200 mg thrice daily for 2 d; 200 mg once daily from 3 d) Caspofungin (70/50 mg once daily) followed by voriconazole iv (6/4 mg/kg BW twice daily) Voriconazole iv (6/4 mg/kg BW twice daily) Caspofungin (70/50 mg once daily) followed by voriconazole iv (6/4 mg/kg BW twice daily) Antiviral therapy Supportive only Supportive only Hydroxychloroquine, darunavir and cobicistat at external hospital, in house changed to supportive only Supportive only Ribavirin, lopinavir/ritonavir at external hospital, in house changed to supportive only Outcome Died Died Alive Died Alive Abbreviations: ARDS, acute respiratory distress syndrome; BALF, bronchoalveolar lavage fluid; BW, body weight; COPD, chronic obstructive pulmonary disease; C t, threshold cycle; EORTC/MSG, European Organization for Research and Treatment of Cancer/Mycoses Study Group; GOLD, global initiative for chronic obstructive lung disease; hMPV, human metapneumovirus; IPA, invasive pulmonary aspergillosis; kg, kilogram; lap, laparoscopic; LVB, lumbar vertebral body; mg, milligram; MIC, minimal inhibitory concentration; MICU, medical ICU; ORF, open reading frame; PCR, polymerase chain reaction; PY, pack‐year history; SICU, surgical ICU; SLEDD, slow low‐efficient daily dialysis; TA, tracheal aspirate; vvECMO, veno‐venous extracorporeal membrane oxygenation. a Antifungal susceptibility testing by VIPcheck™. 6 John Wiley & Sons, Ltd This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency. For patient #1 SARS‐CoV‐2 RT‐PCR Kit (altona Diagnostics) and for patients #2, #3 and #4 cobas® SARS‐CoV‐2 Test (Roche) were used. For patient #5, kit manufacturer remains unknown. Respective C t values are given in Table 1 where available. hMPV‐PCR was performed with NxTAG® Respiratory Pathogen Panel (Luminex). Aspergillus 28S rDNA‐Realtime PCR was performed as in‐house PCR test for screening purposes. Species identification was performed by artus® Aspergillus diff. RG PCR kit (Qiagen). For galactomannan testing from serum, bronchoalveolar lavage fluid (BALF) or tracheal aspirate (TA) Platelia Aspergillus antigen ELISA (Bio‐Rad Laboratories) was used. Antifungal susceptibility testing was performed using concentration gradient strips on RPMI agar plates. In brief, spore suspensions of the fungal isolates were adjusted to 106 CFU/mL and inoculated with MIC test strips for itraconazole and voriconazole (bioMérieux). MICs were determined visually after 48 hours of incubation at 35°C. VIPcheck™ (Mediaproducts BV) was performed in patient #1 for early detection of azole resistance. 6 COVID‐19 associated IPA was classified according to the (modified) 3 AspICU algorithm 7 with the addition that positive galactomannan (≥1) from BALF or TA, or two consecutively but separately drawn positive serum samples (≥1) were accepted as entry criterion. 8 Severe SARS‐CoV2 infection with ARDS was accepted as host criterion (acquired immunodeficiency) (Table 1). This study was carried out in accordance with the ethical principles reflected in the Declaration of Helsinki 9 and was approved by the ethic committee of the University Hospital of Cologne (Identifier of the University of Cologne Ethics Committee 20‐1157). 3 RESULTS A 62‐year‐old woman was admitted to our ICU. She was intubated and developed severe ARDS with a Horowitz‐Index of 53 mm Hg. At the contrast‐enhanced CT a combination of emphysema, bilateral ground‐glass opacities with crazy paving and some peripheral nodular consolidations were seen (Video S1, patient #1, Figure 1A). Despite prone positioning, the patient required rescue veno‐venous extracorporeal membrane oxygenation (ECMO). PCR for SARS‐CoV‐2 and human metapneumovirus (hMPV) was positive in BALF. The patient developed severe intrapulmonary bleeding from the right main bronchus, which was stanched by cold lavages and instillation of tranexamic acid. BALF culture grew Aspergillus fumigatus, was positive for galactomannan, and intravenous voriconazole treatment was commenced. FIGURE 1 Chest CT images of patients with COVID‐19 Associated Invasive Pulmonary Aspergillosis. A, Patient #1: Combined bilateral ground‐glass opacities with crazy paving and peripheral nodular consolidations. B, Patient #2: Ground‐glass opacities with small nodular infiltrations of up to 1 cm. C, Patient #3: Bilateral ground‐glass opacities diffuse nodular infiltrates and cystic cavities and partly air crescent sign. D, Patient #4: Bullous emphysema and ground‐glass opacities, interstitial changes and consolidations with nodular infiltrates. E, Patient #5: Ground‐glass opacities, smaller areas with crazy paving pattern, central and peripheral consolidations, and smaller nodular infiltrates A 70‐year‐old man was admitted to the ICU because of ARDS with a Horowitz‐Index of 93 mm Hg. PCR on BALF was tested positive for hMPV, SARS‐CoV‐2 and Aspergillus fumigatus. Two days before, serum galactomannan had turned positive. BALF was tested positive for galactomannan. Chest CT showed ground‐glass opacities with some small nodular infiltrations of up to 1 cm (Video S2, patient #2 Figure 1B). Due to acute renal failure requiring slow low‐efficient daily dialysis (SLEDD) and elevated liver enzymes, intravenous isavuconazole treatment was started. A 54‐year‐old man presented with ARDS with a Horowitz‐Index of 128 mm Hg. TA revealed SARS‐CoV‐2 PCR positive and Aspergillus fumigatus in culture. BALF was positive for galactomannan. Chest CT showed bilateral ground‐glass opacities, diffuse nodular infiltrates and cystic cavities and partly air crescent sign (Video S3, patient #3 Figure 1C). Intravenous voriconazole treatment was initiated. A 73‐year‐old man was transferred to the ICU due to ARDS with PCR on TA tested positive for SARS‐CoV‐2, and Aspergillus fumigatus that also grew in culture. Chest CT showed known bullous emphysema with ground‐glass opacities and consolidations with nodular infiltrates (Video S4, patient #4, Figure 1D). Intravenous voriconazole was begun. A 54‐year‐old woman was transferred to the ICU due to ARDS with PCR on TA tested positive for SARS‐CoV‐2. Serum galactomannan returned positive in two consecutive serum samples. Chest CT showed bilateral ground‐glass opacities, smaller areas with crazy paving pattern, central and peripheral consolidations, and smaller nodular infiltrates (Video S5, patient #5, Figure 1E). Intravenous caspofungin was started. No autopsies were performed. Detailed patient characteristics are given in Table 1. 4 DISCUSSION Patients with ARDS triggered by viral infection, in particular influenza, are prone to invasive aspergillosis even in absence of prior immunodeficiency. 2 , 3 We report putative IPA in five of 19 COVID‐19 patients with moderate to severe ARDS without underlying immunocompromising disease on two separate ICUs. Spontaneous intrapulmonary bleeding and haemoptysis are typical complications of IPA. Ground‐glass opacities characterise COVID‐19 as well as IPA, thus comprehensive microbiological evaluation can prevent missing IPA. By applying strict interpretation of the host and risk factors for invasive aspergillosis according to the European Organization for Research and Treatment of Cancer/Mycoses Study Group definitions the risk of missed diagnosis increases in the COVID‐19 population. 8 However, a most complicated issue in ARDS patients is to differentiate Aspergillus colonisation from invasive disease—especially as radiological imaging is non‐specific. To address this issue, a consensus project will seek to provide standard definitions for invasive fungal disease in critically ill adult patients. 10 Our observations suggest increased risk for critically ill COVID‐19 patients to develop co‐infection with Aspergillus, which is likely to increase mortality rates further. Therefore, testing for the presence of Aspergillus in lower respiratory secretions and galactomannan in consecutive serum samples in COVID‐19 ICU patients should be considered. 11 Our findings need to be confirmed in clinical trials to elucidate the role of potential IPA after COVID‐19. With this report, we aim to call attention to the critical phenomenon of COVID‐19 associated IA in ARDS patients. CONFLICT OF INTEREST PK has received non‐financial scientific grants from Miltenyi Biotec GmbH, Bergisch Gladbach, Germany, and the Cologne Excellence Cluster on Cellular Stress Responses in Aging‐Associated Diseases, University of Cologne, Cologne, Germany, and received lecture honoraria from Akademie für Infektionsmedizin e.V., Astellas Pharma, Gilead Sciences, GPR Academy Ruesselsheim, MSD Sharp & Dohme GmbH, and University Hospital, LMU Munich outside the submitted work. OAC is supported by the German Federal Ministry of Research and Education, is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy—CECAD, EXC 2030—390 661 388 and has received research grants from, is an advisor to, or received lecture honoraria from Actelion, Allecra Therapeutics, Amplyx, Astellas, Basilea, Biosys UK Limited, Cidara, Da Volterra, Entasis, F2G, Gilead, Grupo Biotoscana, Janssen Pharmaceuticals, Matinas, Medicines Company, MedPace, Melinta Therapeutics, Menarini Ricerche, Roche Diagnostics, Merck/MSD, Nabriva Therapeutics, Octapharma, Paratek Pharmaceuticals, Pfizer, PSI, Rempex, Scynexis, Seres Therapeutics, Tetraphase, Vical. BWB is European Resuscitation Council (ERC) Board Director Science and Research; Chairman of the German Resuscitation Council (GRC); Member of the Advanced Life Support (ALS) Task Force of the International Liaison Committee on Resuscitation (ILCOR); Member of the executive committee of the German Interdisciplinary Association for Intensive and Emergency Medicine (DIVI); Associated Editor of the European Journal of Anaesthesiology (EJA), Co‐Editor of ‘Resuscitation’; Editor of the Journal ‘Notfall + Rettungsmedizin’. He received professional fees for lectures from the following companies: Medupdate GmbH, ‘Forum für medizinische Fortbildung (FomF)’, Baxalta Deutschland GmbH, Bayer Vital GmbH, ZOLL Medical Deutschland GmbH, C. R. Bard GmbH, GS Elektromedizinische Geräte G. Stemple GmbH, Novartis Pharma GmbH, Philips GmbH Market DACH. FD reports personal fees from Forum für medizinische Fortbildung GmbH, BioMérieux GmBH, M3 Inc, and pm‐result GmbH, outside the submitted work. FD: Associated Editor of 'BMC Anesthesiology'. DAE has no potential conflict of interest. FF reports scientific grants from the Medical Faculty of the University of Cologne (Maria Pesch grant and GEROK grant), outside the submitted work. MH reports grants from Roche, personal fees from Roche, personal fees from Roche, grants from Abbvie, personal fees from Abbvie, personal fees from Abbvie, during the conduct of the study; grants from Gilead, personal fees from Gilead, personal fees from Gilead, grants from Janssen, personal fees from Janssen, personal fees from Janssen, personal fees from Celgene, personal fees from Celgene, personal fees from Boehringer Ingelheim, personal fees from Boehringer Ingelheim, outside the submitted work. NJ reports lecture fees from Gilead, Infectopharm and MSD and travel grants from Gilead, Basilea, Correvio and Pfizer outside the submitted work. FK is supported by the German Center for Infection Research (DZIF), the German Research Foundation (CRC 1279 and CRC 1310), the Bill and Melinda Gates Foundation, and the European Research Council (ERC‐StG639961). FK received lecture and consulting honoraria from MSD, Roche and ViiV outside the submitted work. TP has no potential conflict of interest. JR has nothing to disclose. MK reports personal fees from Pfizer, Astellas Pharma, Gilead Sciences and MSD Sharp & Dohme GmbH outside the submitted work. BB is a consultant to Baxalta, Celgene, MSD, Mundipharma and received Honoraria and Research funding from Astellas, Celgene, J&J, Maquet, Miltenyi, MSD, Takeda, Roche and Sanofi. ASV reports travel grants from Gilead Sciences outside the submitted work. AUTHOR CONTRIBUTIONS Philipp Koehler: Conceptualization (lead); Investigation (lead); Writing‐original draft (lead); Writing‐review & editing (lead). Oliver A. Cornely: Conceptualization (lead); Investigation (lead); Writing‐original draft (lead); Writing‐review & editing (lead). Bernd W. Böttiger: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Fabian Dusse: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Dennis A. Eichenauer: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Frieder Fuchs: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Michael Hallek: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Norma Jung: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Florian Klein: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Thorsten Persigehl: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Jan Rybniker: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Matthias Kochanek: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Boris Böll: Investigation (lead); Writing‐original draft (lead); Writing‐review & editing (lead). Alexander Shimabukuro‐Vornhagen: Investigation (lead); Writing‐original draft (lead); Writing‐review & editing (lead). ETHICAL APPROVAL The authors confirm that the ethical policies of the journal, as noted in the author's guideline page, have been adhered to. Our study was approved by the ethic committee of the University Hospital of Cologne (Identifier of the University of Cologne Ethics Committee 20‐1157). Supporting information Video S1 Click here for additional data file. Video S2 Click here for additional data file. Video S3 Click here for additional data file. Video S4 Click here for additional data file. Video S5 Click here for additional data file. Supplementary Material Click here for additional data file. ACKNOWLEDGMENT The authors thank Susann Blossfeld for technical assistance.

Document structure show

article-title	COVID‐19 associated pulmonary aspergillosis
alt-title	KOEHLER et al
abstract	Summary Objectives Patients with acute respiratory distress syndrome (ARDS) due to viral infection are at risk for secondary complications like invasive aspergillosis. Our study evaluates coronavirus disease 19 (COVID‐19) associated invasive aspergillosis at a single centre in Cologne, Germany. Methods A retrospective chart review of all patients with COVID‐19 associated ARDS admitted to the medical or surgical intensive care unit at the University Hospital of Cologne, Cologne, Germany. Results COVID‐19 associated invasive pulmonary aspergillosis was found in five of 19 consecutive critically ill patients with moderate to severe ARDS. Conclusion Clinicians caring for patients with ARDS due to COVID‐19 should consider invasive pulmonary aspergillosis and subject respiratory samples to comprehensive analysis to detect co‐infection.
title	Summary
sec	Objectives Patients with acute respiratory distress syndrome (ARDS) due to viral infection are at risk for secondary complications like invasive aspergillosis. Our study evaluates coronavirus disease 19 (COVID‐19) associated invasive aspergillosis at a single centre in Cologne, Germany.
title	Objectives
p	Patients with acute respiratory distress syndrome (ARDS) due to viral infection are at risk for secondary complications like invasive aspergillosis. Our study evaluates coronavirus disease 19 (COVID‐19) associated invasive aspergillosis at a single centre in Cologne, Germany.
sec	Methods A retrospective chart review of all patients with COVID‐19 associated ARDS admitted to the medical or surgical intensive care unit at the University Hospital of Cologne, Cologne, Germany.
title	Methods
p	A retrospective chart review of all patients with COVID‐19 associated ARDS admitted to the medical or surgical intensive care unit at the University Hospital of Cologne, Cologne, Germany.
sec	Results COVID‐19 associated invasive pulmonary aspergillosis was found in five of 19 consecutive critically ill patients with moderate to severe ARDS.
title	Results
p	COVID‐19 associated invasive pulmonary aspergillosis was found in five of 19 consecutive critically ill patients with moderate to severe ARDS.
sec	Conclusion Clinicians caring for patients with ARDS due to COVID‐19 should consider invasive pulmonary aspergillosis and subject respiratory samples to comprehensive analysis to detect co‐infection.
title	Conclusion
p	Clinicians caring for patients with ARDS due to COVID‐19 should consider invasive pulmonary aspergillosis and subject respiratory samples to comprehensive analysis to detect co‐infection.
body	1 INTRODUCTION Since December 2019 coronavirus disease 2019 (COVID‐19) emerged from Wuhan City, Hubei province, China and rapidly spread around the globe becoming a pandemic threat. 1 Risk factors for invasive pulmonary aspergillosis (IPA) are well defined in immunocompromised populations. However, patients with acute respiratory distress syndrome (ARDS) due to viral infection are prone to secondary complications like invasive aspergillosis despite lack of underlying well‐defined immunocompromising disease. 2 , 3 , 4 Possible explanations for this could be an immune‐paralysis caused by viral infection‐induced ARDS and hypoxia compromising the innate host defence. 5 In light of influenza‐pulmonary associated aspergillosis, we retrospectively analysed our patients with COVID‐19 associated ARDS in the intensive care unit (ICU) at a single centre. 2 PATIENTS AND METHODS We performed a retrospective chart review of patients with COVID‐19 and ARDS admitted to the medical and surgical ICU at the University Hospital of Cologne, a 1540‐bed teaching hospital between 7 March 2020 and 22 April 2020 (Table 1). TABLE 1 Patient characteristics of patients with COVID‐19 associated invasive pulmonary aspergillosis Characteristics Patient #1 Patient #2 Patient #3 Patient #4 Patient #5 Gender Female Male Male Male Female Age (y) 62 70 54 73 54 Medical history Lap. cholecystectomy for cholecystitis Arterial hypertension Obesity with sleep apnea (BMI 31.5) Hypercholesterolemia Ex‐smoker (30 PY; 5 y previously) Moderate COPD (GOLD 2) Vertebral disc prolapse left L4/5, flavectomy and nucleotomy Ex‐smoker (4 months previously) Arterial hypertension Diabetes mellitus Aneurysm coiling right A. vertebralis Arterial hypertension Bullous Emphysema Smoker Severe COPD (GOLD 3) Previous Hepatitis B No Underlying immuno‐compromising condition (inhalational steroids for COPD) No (intravenous corticosteroid therapy 0.4 mg/kg/d, total of 13 d) (inhalational steroids for COPD) No ICU Ward MICU MICU SICU SICU MICU ARDS Horowitz‐Index, admission 12 Severe (53 mm Hg) Severe (93 mm Hg) Moderate (128 mm Hg) Severe (83 mm Hg) Moderate (167 mm Hg) Prone positioning Yes Yes Yes Yes Yes vvECMO Yes No No No No Acute renal failure Yes Yes Yes Yes Yes Dialysis No SLEDD SLEDD SLEDD No Microbiology Serum GM (>0.5) Negative Positive (0.7) Negative Negative 2× positive (2.7 and 1.3) Fungal culture BALF: Aspergillus fumigatus BALF: negative TA: Aspergillus fumigatus TA: Aspergillus fumigatus TA: negative Susceptibility testing Azole susceptible a Not applicable Azole susceptible Itraconazole MIC 0.380 (mg/L) Voriconazole MIC 0.094 (mg/L) Azole susceptible Itraconazole MIC 0.380 (mg/L) Voriconazole MIC 0.094 (mg/L) Not applicable Fungal PCR BALF: Aspergillus fumigatus BALF: Aspergillus fumigatus BALF: Aspergillus fumigatus TA: Aspergillus fumigatus TA: negative TA/BALF GM (>0.5) BALF: Positive (>2.5) BALF: Positive (>2.5) BALF: Positive (>2.5) Not available Not available Definition of IPA EORTC/MSG Criteria 8 Not classifiable (no host criterion) Not classifiable (no host criterion) Not classifiable (no host criterion) Not classifiable (no host criterion) Not classifiable (no host criterion) (modified) AspICU algorithm 3 , 7 Putative Modified putative 3 (GM positivity) Putative Putative Modified putative 3 (GM positivity) Virology PCR TA: positive for hMPV and SARS‐CoV‐2 (E‐gene: C t 13.29; S‐gene: C t 12.61) TA: positive for hMPV and SARS‐CoV‐2(E‐gene: C t 34.29; ORF1 a/b: C t 31.47) TA positive for SARS‐CoV‐2 (E‐gene: C t 29.74; ORF1 a/b: C t 27.86) TA positive for SARS‐CoV‐2 (E‐gene: C t 21.47; ORF1 a/b: C t 20.12) TA positive for SARS‐CoV‐2 (C t values not available) CT imaging studies Combined bilateral ground‐glass opacities with crazy paving and peripheral nodular consolidations (Video S1, Figure 1A) Ground‐glass opacities with occasional nodules (Video S2, Figure 1B) Bilateral ground‐glass opacities, nodular infiltrates with cavities and air crescent sign (Video S3, Figure 1C) Ground‐glass opacities with occasional nodules, known bullous emphysema (Video S4, Figure 1D) Ground‐glass opacities, smaller areas with crazy paving pattern, central and peripheral consolidations, and smaller nodular infiltrates (Video S5, Figure 1E) Therapy Antifungal treatment Voriconazole iv (6/4 mg/kg BW twice daily) Isavuconazole iv (200 mg thrice daily for 2 d; 200 mg once daily from 3 d) Caspofungin (70/50 mg once daily) followed by voriconazole iv (6/4 mg/kg BW twice daily) Voriconazole iv (6/4 mg/kg BW twice daily) Caspofungin (70/50 mg once daily) followed by voriconazole iv (6/4 mg/kg BW twice daily) Antiviral therapy Supportive only Supportive only Hydroxychloroquine, darunavir and cobicistat at external hospital, in house changed to supportive only Supportive only Ribavirin, lopinavir/ritonavir at external hospital, in house changed to supportive only Outcome Died Died Alive Died Alive Abbreviations: ARDS, acute respiratory distress syndrome; BALF, bronchoalveolar lavage fluid; BW, body weight; COPD, chronic obstructive pulmonary disease; C t, threshold cycle; EORTC/MSG, European Organization for Research and Treatment of Cancer/Mycoses Study Group; GOLD, global initiative for chronic obstructive lung disease; hMPV, human metapneumovirus; IPA, invasive pulmonary aspergillosis; kg, kilogram; lap, laparoscopic; LVB, lumbar vertebral body; mg, milligram; MIC, minimal inhibitory concentration; MICU, medical ICU; ORF, open reading frame; PCR, polymerase chain reaction; PY, pack‐year history; SICU, surgical ICU; SLEDD, slow low‐efficient daily dialysis; TA, tracheal aspirate; vvECMO, veno‐venous extracorporeal membrane oxygenation. a Antifungal susceptibility testing by VIPcheck™. 6 John Wiley & Sons, Ltd This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency. For patient #1 SARS‐CoV‐2 RT‐PCR Kit (altona Diagnostics) and for patients #2, #3 and #4 cobas® SARS‐CoV‐2 Test (Roche) were used. For patient #5, kit manufacturer remains unknown. Respective C t values are given in Table 1 where available. hMPV‐PCR was performed with NxTAG® Respiratory Pathogen Panel (Luminex). Aspergillus 28S rDNA‐Realtime PCR was performed as in‐house PCR test for screening purposes. Species identification was performed by artus® Aspergillus diff. RG PCR kit (Qiagen). For galactomannan testing from serum, bronchoalveolar lavage fluid (BALF) or tracheal aspirate (TA) Platelia Aspergillus antigen ELISA (Bio‐Rad Laboratories) was used. Antifungal susceptibility testing was performed using concentration gradient strips on RPMI agar plates. In brief, spore suspensions of the fungal isolates were adjusted to 106 CFU/mL and inoculated with MIC test strips for itraconazole and voriconazole (bioMérieux). MICs were determined visually after 48 hours of incubation at 35°C. VIPcheck™ (Mediaproducts BV) was performed in patient #1 for early detection of azole resistance. 6 COVID‐19 associated IPA was classified according to the (modified) 3 AspICU algorithm 7 with the addition that positive galactomannan (≥1) from BALF or TA, or two consecutively but separately drawn positive serum samples (≥1) were accepted as entry criterion. 8 Severe SARS‐CoV2 infection with ARDS was accepted as host criterion (acquired immunodeficiency) (Table 1). This study was carried out in accordance with the ethical principles reflected in the Declaration of Helsinki 9 and was approved by the ethic committee of the University Hospital of Cologne (Identifier of the University of Cologne Ethics Committee 20‐1157). 3 RESULTS A 62‐year‐old woman was admitted to our ICU. She was intubated and developed severe ARDS with a Horowitz‐Index of 53 mm Hg. At the contrast‐enhanced CT a combination of emphysema, bilateral ground‐glass opacities with crazy paving and some peripheral nodular consolidations were seen (Video S1, patient #1, Figure 1A). Despite prone positioning, the patient required rescue veno‐venous extracorporeal membrane oxygenation (ECMO). PCR for SARS‐CoV‐2 and human metapneumovirus (hMPV) was positive in BALF. The patient developed severe intrapulmonary bleeding from the right main bronchus, which was stanched by cold lavages and instillation of tranexamic acid. BALF culture grew Aspergillus fumigatus, was positive for galactomannan, and intravenous voriconazole treatment was commenced. FIGURE 1 Chest CT images of patients with COVID‐19 Associated Invasive Pulmonary Aspergillosis. A, Patient #1: Combined bilateral ground‐glass opacities with crazy paving and peripheral nodular consolidations. B, Patient #2: Ground‐glass opacities with small nodular infiltrations of up to 1 cm. C, Patient #3: Bilateral ground‐glass opacities diffuse nodular infiltrates and cystic cavities and partly air crescent sign. D, Patient #4: Bullous emphysema and ground‐glass opacities, interstitial changes and consolidations with nodular infiltrates. E, Patient #5: Ground‐glass opacities, smaller areas with crazy paving pattern, central and peripheral consolidations, and smaller nodular infiltrates A 70‐year‐old man was admitted to the ICU because of ARDS with a Horowitz‐Index of 93 mm Hg. PCR on BALF was tested positive for hMPV, SARS‐CoV‐2 and Aspergillus fumigatus. Two days before, serum galactomannan had turned positive. BALF was tested positive for galactomannan. Chest CT showed ground‐glass opacities with some small nodular infiltrations of up to 1 cm (Video S2, patient #2 Figure 1B). Due to acute renal failure requiring slow low‐efficient daily dialysis (SLEDD) and elevated liver enzymes, intravenous isavuconazole treatment was started. A 54‐year‐old man presented with ARDS with a Horowitz‐Index of 128 mm Hg. TA revealed SARS‐CoV‐2 PCR positive and Aspergillus fumigatus in culture. BALF was positive for galactomannan. Chest CT showed bilateral ground‐glass opacities, diffuse nodular infiltrates and cystic cavities and partly air crescent sign (Video S3, patient #3 Figure 1C). Intravenous voriconazole treatment was initiated. A 73‐year‐old man was transferred to the ICU due to ARDS with PCR on TA tested positive for SARS‐CoV‐2, and Aspergillus fumigatus that also grew in culture. Chest CT showed known bullous emphysema with ground‐glass opacities and consolidations with nodular infiltrates (Video S4, patient #4, Figure 1D). Intravenous voriconazole was begun. A 54‐year‐old woman was transferred to the ICU due to ARDS with PCR on TA tested positive for SARS‐CoV‐2. Serum galactomannan returned positive in two consecutive serum samples. Chest CT showed bilateral ground‐glass opacities, smaller areas with crazy paving pattern, central and peripheral consolidations, and smaller nodular infiltrates (Video S5, patient #5, Figure 1E). Intravenous caspofungin was started. No autopsies were performed. Detailed patient characteristics are given in Table 1. 4 DISCUSSION Patients with ARDS triggered by viral infection, in particular influenza, are prone to invasive aspergillosis even in absence of prior immunodeficiency. 2 , 3 We report putative IPA in five of 19 COVID‐19 patients with moderate to severe ARDS without underlying immunocompromising disease on two separate ICUs. Spontaneous intrapulmonary bleeding and haemoptysis are typical complications of IPA. Ground‐glass opacities characterise COVID‐19 as well as IPA, thus comprehensive microbiological evaluation can prevent missing IPA. By applying strict interpretation of the host and risk factors for invasive aspergillosis according to the European Organization for Research and Treatment of Cancer/Mycoses Study Group definitions the risk of missed diagnosis increases in the COVID‐19 population. 8 However, a most complicated issue in ARDS patients is to differentiate Aspergillus colonisation from invasive disease—especially as radiological imaging is non‐specific. To address this issue, a consensus project will seek to provide standard definitions for invasive fungal disease in critically ill adult patients. 10 Our observations suggest increased risk for critically ill COVID‐19 patients to develop co‐infection with Aspergillus, which is likely to increase mortality rates further. Therefore, testing for the presence of Aspergillus in lower respiratory secretions and galactomannan in consecutive serum samples in COVID‐19 ICU patients should be considered. 11 Our findings need to be confirmed in clinical trials to elucidate the role of potential IPA after COVID‐19. With this report, we aim to call attention to the critical phenomenon of COVID‐19 associated IA in ARDS patients. CONFLICT OF INTEREST PK has received non‐financial scientific grants from Miltenyi Biotec GmbH, Bergisch Gladbach, Germany, and the Cologne Excellence Cluster on Cellular Stress Responses in Aging‐Associated Diseases, University of Cologne, Cologne, Germany, and received lecture honoraria from Akademie für Infektionsmedizin e.V., Astellas Pharma, Gilead Sciences, GPR Academy Ruesselsheim, MSD Sharp & Dohme GmbH, and University Hospital, LMU Munich outside the submitted work. OAC is supported by the German Federal Ministry of Research and Education, is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy—CECAD, EXC 2030—390 661 388 and has received research grants from, is an advisor to, or received lecture honoraria from Actelion, Allecra Therapeutics, Amplyx, Astellas, Basilea, Biosys UK Limited, Cidara, Da Volterra, Entasis, F2G, Gilead, Grupo Biotoscana, Janssen Pharmaceuticals, Matinas, Medicines Company, MedPace, Melinta Therapeutics, Menarini Ricerche, Roche Diagnostics, Merck/MSD, Nabriva Therapeutics, Octapharma, Paratek Pharmaceuticals, Pfizer, PSI, Rempex, Scynexis, Seres Therapeutics, Tetraphase, Vical. BWB is European Resuscitation Council (ERC) Board Director Science and Research; Chairman of the German Resuscitation Council (GRC); Member of the Advanced Life Support (ALS) Task Force of the International Liaison Committee on Resuscitation (ILCOR); Member of the executive committee of the German Interdisciplinary Association for Intensive and Emergency Medicine (DIVI); Associated Editor of the European Journal of Anaesthesiology (EJA), Co‐Editor of ‘Resuscitation’; Editor of the Journal ‘Notfall + Rettungsmedizin’. He received professional fees for lectures from the following companies: Medupdate GmbH, ‘Forum für medizinische Fortbildung (FomF)’, Baxalta Deutschland GmbH, Bayer Vital GmbH, ZOLL Medical Deutschland GmbH, C. R. Bard GmbH, GS Elektromedizinische Geräte G. Stemple GmbH, Novartis Pharma GmbH, Philips GmbH Market DACH. FD reports personal fees from Forum für medizinische Fortbildung GmbH, BioMérieux GmBH, M3 Inc, and pm‐result GmbH, outside the submitted work. FD: Associated Editor of 'BMC Anesthesiology'. DAE has no potential conflict of interest. FF reports scientific grants from the Medical Faculty of the University of Cologne (Maria Pesch grant and GEROK grant), outside the submitted work. MH reports grants from Roche, personal fees from Roche, personal fees from Roche, grants from Abbvie, personal fees from Abbvie, personal fees from Abbvie, during the conduct of the study; grants from Gilead, personal fees from Gilead, personal fees from Gilead, grants from Janssen, personal fees from Janssen, personal fees from Janssen, personal fees from Celgene, personal fees from Celgene, personal fees from Boehringer Ingelheim, personal fees from Boehringer Ingelheim, outside the submitted work. NJ reports lecture fees from Gilead, Infectopharm and MSD and travel grants from Gilead, Basilea, Correvio and Pfizer outside the submitted work. FK is supported by the German Center for Infection Research (DZIF), the German Research Foundation (CRC 1279 and CRC 1310), the Bill and Melinda Gates Foundation, and the European Research Council (ERC‐StG639961). FK received lecture and consulting honoraria from MSD, Roche and ViiV outside the submitted work. TP has no potential conflict of interest. JR has nothing to disclose. MK reports personal fees from Pfizer, Astellas Pharma, Gilead Sciences and MSD Sharp & Dohme GmbH outside the submitted work. BB is a consultant to Baxalta, Celgene, MSD, Mundipharma and received Honoraria and Research funding from Astellas, Celgene, J&J, Maquet, Miltenyi, MSD, Takeda, Roche and Sanofi. ASV reports travel grants from Gilead Sciences outside the submitted work. AUTHOR CONTRIBUTIONS Philipp Koehler: Conceptualization (lead); Investigation (lead); Writing‐original draft (lead); Writing‐review & editing (lead). Oliver A. Cornely: Conceptualization (lead); Investigation (lead); Writing‐original draft (lead); Writing‐review & editing (lead). Bernd W. Böttiger: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Fabian Dusse: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Dennis A. Eichenauer: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Frieder Fuchs: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Michael Hallek: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Norma Jung: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Florian Klein: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Thorsten Persigehl: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Jan Rybniker: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Matthias Kochanek: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Boris Böll: Investigation (lead); Writing‐original draft (lead); Writing‐review & editing (lead). Alexander Shimabukuro‐Vornhagen: Investigation (lead); Writing‐original draft (lead); Writing‐review & editing (lead). ETHICAL APPROVAL The authors confirm that the ethical policies of the journal, as noted in the author's guideline page, have been adhered to. Our study was approved by the ethic committee of the University Hospital of Cologne (Identifier of the University of Cologne Ethics Committee 20‐1157). Supporting information Video S1 Click here for additional data file. Video S2 Click here for additional data file. Video S3 Click here for additional data file. Video S4 Click here for additional data file. Video S5 Click here for additional data file. Supplementary Material Click here for additional data file.
sec	1 INTRODUCTION Since December 2019 coronavirus disease 2019 (COVID‐19) emerged from Wuhan City, Hubei province, China and rapidly spread around the globe becoming a pandemic threat. 1 Risk factors for invasive pulmonary aspergillosis (IPA) are well defined in immunocompromised populations. However, patients with acute respiratory distress syndrome (ARDS) due to viral infection are prone to secondary complications like invasive aspergillosis despite lack of underlying well‐defined immunocompromising disease. 2 , 3 , 4 Possible explanations for this could be an immune‐paralysis caused by viral infection‐induced ARDS and hypoxia compromising the innate host defence. 5 In light of influenza‐pulmonary associated aspergillosis, we retrospectively analysed our patients with COVID‐19 associated ARDS in the intensive care unit (ICU) at a single centre.
label	1
title	INTRODUCTION
p	Since December 2019 coronavirus disease 2019 (COVID‐19) emerged from Wuhan City, Hubei province, China and rapidly spread around the globe becoming a pandemic threat. 1 Risk factors for invasive pulmonary aspergillosis (IPA) are well defined in immunocompromised populations. However, patients with acute respiratory distress syndrome (ARDS) due to viral infection are prone to secondary complications like invasive aspergillosis despite lack of underlying well‐defined immunocompromising disease. 2 , 3 , 4 Possible explanations for this could be an immune‐paralysis caused by viral infection‐induced ARDS and hypoxia compromising the innate host defence. 5 In light of influenza‐pulmonary associated aspergillosis, we retrospectively analysed our patients with COVID‐19 associated ARDS in the intensive care unit (ICU) at a single centre.
sec	2 PATIENTS AND METHODS We performed a retrospective chart review of patients with COVID‐19 and ARDS admitted to the medical and surgical ICU at the University Hospital of Cologne, a 1540‐bed teaching hospital between 7 March 2020 and 22 April 2020 (Table 1). TABLE 1 Patient characteristics of patients with COVID‐19 associated invasive pulmonary aspergillosis Characteristics Patient #1 Patient #2 Patient #3 Patient #4 Patient #5 Gender Female Male Male Male Female Age (y) 62 70 54 73 54 Medical history Lap. cholecystectomy for cholecystitis Arterial hypertension Obesity with sleep apnea (BMI 31.5) Hypercholesterolemia Ex‐smoker (30 PY; 5 y previously) Moderate COPD (GOLD 2) Vertebral disc prolapse left L4/5, flavectomy and nucleotomy Ex‐smoker (4 months previously) Arterial hypertension Diabetes mellitus Aneurysm coiling right A. vertebralis Arterial hypertension Bullous Emphysema Smoker Severe COPD (GOLD 3) Previous Hepatitis B No Underlying immuno‐compromising condition (inhalational steroids for COPD) No (intravenous corticosteroid therapy 0.4 mg/kg/d, total of 13 d) (inhalational steroids for COPD) No ICU Ward MICU MICU SICU SICU MICU ARDS Horowitz‐Index, admission 12 Severe (53 mm Hg) Severe (93 mm Hg) Moderate (128 mm Hg) Severe (83 mm Hg) Moderate (167 mm Hg) Prone positioning Yes Yes Yes Yes Yes vvECMO Yes No No No No Acute renal failure Yes Yes Yes Yes Yes Dialysis No SLEDD SLEDD SLEDD No Microbiology Serum GM (>0.5) Negative Positive (0.7) Negative Negative 2× positive (2.7 and 1.3) Fungal culture BALF: Aspergillus fumigatus BALF: negative TA: Aspergillus fumigatus TA: Aspergillus fumigatus TA: negative Susceptibility testing Azole susceptible a Not applicable Azole susceptible Itraconazole MIC 0.380 (mg/L) Voriconazole MIC 0.094 (mg/L) Azole susceptible Itraconazole MIC 0.380 (mg/L) Voriconazole MIC 0.094 (mg/L) Not applicable Fungal PCR BALF: Aspergillus fumigatus BALF: Aspergillus fumigatus BALF: Aspergillus fumigatus TA: Aspergillus fumigatus TA: negative TA/BALF GM (>0.5) BALF: Positive (>2.5) BALF: Positive (>2.5) BALF: Positive (>2.5) Not available Not available Definition of IPA EORTC/MSG Criteria 8 Not classifiable (no host criterion) Not classifiable (no host criterion) Not classifiable (no host criterion) Not classifiable (no host criterion) Not classifiable (no host criterion) (modified) AspICU algorithm 3 , 7 Putative Modified putative 3 (GM positivity) Putative Putative Modified putative 3 (GM positivity) Virology PCR TA: positive for hMPV and SARS‐CoV‐2 (E‐gene: C t 13.29; S‐gene: C t 12.61) TA: positive for hMPV and SARS‐CoV‐2(E‐gene: C t 34.29; ORF1 a/b: C t 31.47) TA positive for SARS‐CoV‐2 (E‐gene: C t 29.74; ORF1 a/b: C t 27.86) TA positive for SARS‐CoV‐2 (E‐gene: C t 21.47; ORF1 a/b: C t 20.12) TA positive for SARS‐CoV‐2 (C t values not available) CT imaging studies Combined bilateral ground‐glass opacities with crazy paving and peripheral nodular consolidations (Video S1, Figure 1A) Ground‐glass opacities with occasional nodules (Video S2, Figure 1B) Bilateral ground‐glass opacities, nodular infiltrates with cavities and air crescent sign (Video S3, Figure 1C) Ground‐glass opacities with occasional nodules, known bullous emphysema (Video S4, Figure 1D) Ground‐glass opacities, smaller areas with crazy paving pattern, central and peripheral consolidations, and smaller nodular infiltrates (Video S5, Figure 1E) Therapy Antifungal treatment Voriconazole iv (6/4 mg/kg BW twice daily) Isavuconazole iv (200 mg thrice daily for 2 d; 200 mg once daily from 3 d) Caspofungin (70/50 mg once daily) followed by voriconazole iv (6/4 mg/kg BW twice daily) Voriconazole iv (6/4 mg/kg BW twice daily) Caspofungin (70/50 mg once daily) followed by voriconazole iv (6/4 mg/kg BW twice daily) Antiviral therapy Supportive only Supportive only Hydroxychloroquine, darunavir and cobicistat at external hospital, in house changed to supportive only Supportive only Ribavirin, lopinavir/ritonavir at external hospital, in house changed to supportive only Outcome Died Died Alive Died Alive Abbreviations: ARDS, acute respiratory distress syndrome; BALF, bronchoalveolar lavage fluid; BW, body weight; COPD, chronic obstructive pulmonary disease; C t, threshold cycle; EORTC/MSG, European Organization for Research and Treatment of Cancer/Mycoses Study Group; GOLD, global initiative for chronic obstructive lung disease; hMPV, human metapneumovirus; IPA, invasive pulmonary aspergillosis; kg, kilogram; lap, laparoscopic; LVB, lumbar vertebral body; mg, milligram; MIC, minimal inhibitory concentration; MICU, medical ICU; ORF, open reading frame; PCR, polymerase chain reaction; PY, pack‐year history; SICU, surgical ICU; SLEDD, slow low‐efficient daily dialysis; TA, tracheal aspirate; vvECMO, veno‐venous extracorporeal membrane oxygenation. a Antifungal susceptibility testing by VIPcheck™. 6 John Wiley & Sons, Ltd This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency. For patient #1 SARS‐CoV‐2 RT‐PCR Kit (altona Diagnostics) and for patients #2, #3 and #4 cobas® SARS‐CoV‐2 Test (Roche) were used. For patient #5, kit manufacturer remains unknown. Respective C t values are given in Table 1 where available. hMPV‐PCR was performed with NxTAG® Respiratory Pathogen Panel (Luminex). Aspergillus 28S rDNA‐Realtime PCR was performed as in‐house PCR test for screening purposes. Species identification was performed by artus® Aspergillus diff. RG PCR kit (Qiagen). For galactomannan testing from serum, bronchoalveolar lavage fluid (BALF) or tracheal aspirate (TA) Platelia Aspergillus antigen ELISA (Bio‐Rad Laboratories) was used. Antifungal susceptibility testing was performed using concentration gradient strips on RPMI agar plates. In brief, spore suspensions of the fungal isolates were adjusted to 106 CFU/mL and inoculated with MIC test strips for itraconazole and voriconazole (bioMérieux). MICs were determined visually after 48 hours of incubation at 35°C. VIPcheck™ (Mediaproducts BV) was performed in patient #1 for early detection of azole resistance. 6 COVID‐19 associated IPA was classified according to the (modified) 3 AspICU algorithm 7 with the addition that positive galactomannan (≥1) from BALF or TA, or two consecutively but separately drawn positive serum samples (≥1) were accepted as entry criterion. 8 Severe SARS‐CoV2 infection with ARDS was accepted as host criterion (acquired immunodeficiency) (Table 1). This study was carried out in accordance with the ethical principles reflected in the Declaration of Helsinki 9 and was approved by the ethic committee of the University Hospital of Cologne (Identifier of the University of Cologne Ethics Committee 20‐1157).
label	2
title	PATIENTS AND METHODS
p	We performed a retrospective chart review of patients with COVID‐19 and ARDS admitted to the medical and surgical ICU at the University Hospital of Cologne, a 1540‐bed teaching hospital between 7 March 2020 and 22 April 2020 (Table 1).
table-wrap	TABLE 1 Patient characteristics of patients with COVID‐19 associated invasive pulmonary aspergillosis Characteristics Patient #1 Patient #2 Patient #3 Patient #4 Patient #5 Gender Female Male Male Male Female Age (y) 62 70 54 73 54 Medical history Lap. cholecystectomy for cholecystitis Arterial hypertension Obesity with sleep apnea (BMI 31.5) Hypercholesterolemia Ex‐smoker (30 PY; 5 y previously) Moderate COPD (GOLD 2) Vertebral disc prolapse left L4/5, flavectomy and nucleotomy Ex‐smoker (4 months previously) Arterial hypertension Diabetes mellitus Aneurysm coiling right A. vertebralis Arterial hypertension Bullous Emphysema Smoker Severe COPD (GOLD 3) Previous Hepatitis B No Underlying immuno‐compromising condition (inhalational steroids for COPD) No (intravenous corticosteroid therapy 0.4 mg/kg/d, total of 13 d) (inhalational steroids for COPD) No ICU Ward MICU MICU SICU SICU MICU ARDS Horowitz‐Index, admission 12 Severe (53 mm Hg) Severe (93 mm Hg) Moderate (128 mm Hg) Severe (83 mm Hg) Moderate (167 mm Hg) Prone positioning Yes Yes Yes Yes Yes vvECMO Yes No No No No Acute renal failure Yes Yes Yes Yes Yes Dialysis No SLEDD SLEDD SLEDD No Microbiology Serum GM (>0.5) Negative Positive (0.7) Negative Negative 2× positive (2.7 and 1.3) Fungal culture BALF: Aspergillus fumigatus BALF: negative TA: Aspergillus fumigatus TA: Aspergillus fumigatus TA: negative Susceptibility testing Azole susceptible a Not applicable Azole susceptible Itraconazole MIC 0.380 (mg/L) Voriconazole MIC 0.094 (mg/L) Azole susceptible Itraconazole MIC 0.380 (mg/L) Voriconazole MIC 0.094 (mg/L) Not applicable Fungal PCR BALF: Aspergillus fumigatus BALF: Aspergillus fumigatus BALF: Aspergillus fumigatus TA: Aspergillus fumigatus TA: negative TA/BALF GM (>0.5) BALF: Positive (>2.5) BALF: Positive (>2.5) BALF: Positive (>2.5) Not available Not available Definition of IPA EORTC/MSG Criteria 8 Not classifiable (no host criterion) Not classifiable (no host criterion) Not classifiable (no host criterion) Not classifiable (no host criterion) Not classifiable (no host criterion) (modified) AspICU algorithm 3 , 7 Putative Modified putative 3 (GM positivity) Putative Putative Modified putative 3 (GM positivity) Virology PCR TA: positive for hMPV and SARS‐CoV‐2 (E‐gene: C t 13.29; S‐gene: C t 12.61) TA: positive for hMPV and SARS‐CoV‐2(E‐gene: C t 34.29; ORF1 a/b: C t 31.47) TA positive for SARS‐CoV‐2 (E‐gene: C t 29.74; ORF1 a/b: C t 27.86) TA positive for SARS‐CoV‐2 (E‐gene: C t 21.47; ORF1 a/b: C t 20.12) TA positive for SARS‐CoV‐2 (C t values not available) CT imaging studies Combined bilateral ground‐glass opacities with crazy paving and peripheral nodular consolidations (Video S1, Figure 1A) Ground‐glass opacities with occasional nodules (Video S2, Figure 1B) Bilateral ground‐glass opacities, nodular infiltrates with cavities and air crescent sign (Video S3, Figure 1C) Ground‐glass opacities with occasional nodules, known bullous emphysema (Video S4, Figure 1D) Ground‐glass opacities, smaller areas with crazy paving pattern, central and peripheral consolidations, and smaller nodular infiltrates (Video S5, Figure 1E) Therapy Antifungal treatment Voriconazole iv (6/4 mg/kg BW twice daily) Isavuconazole iv (200 mg thrice daily for 2 d; 200 mg once daily from 3 d) Caspofungin (70/50 mg once daily) followed by voriconazole iv (6/4 mg/kg BW twice daily) Voriconazole iv (6/4 mg/kg BW twice daily) Caspofungin (70/50 mg once daily) followed by voriconazole iv (6/4 mg/kg BW twice daily) Antiviral therapy Supportive only Supportive only Hydroxychloroquine, darunavir and cobicistat at external hospital, in house changed to supportive only Supportive only Ribavirin, lopinavir/ritonavir at external hospital, in house changed to supportive only Outcome Died Died Alive Died Alive Abbreviations: ARDS, acute respiratory distress syndrome; BALF, bronchoalveolar lavage fluid; BW, body weight; COPD, chronic obstructive pulmonary disease; C t, threshold cycle; EORTC/MSG, European Organization for Research and Treatment of Cancer/Mycoses Study Group; GOLD, global initiative for chronic obstructive lung disease; hMPV, human metapneumovirus; IPA, invasive pulmonary aspergillosis; kg, kilogram; lap, laparoscopic; LVB, lumbar vertebral body; mg, milligram; MIC, minimal inhibitory concentration; MICU, medical ICU; ORF, open reading frame; PCR, polymerase chain reaction; PY, pack‐year history; SICU, surgical ICU; SLEDD, slow low‐efficient daily dialysis; TA, tracheal aspirate; vvECMO, veno‐venous extracorporeal membrane oxygenation. a Antifungal susceptibility testing by VIPcheck™. 6 John Wiley & Sons, Ltd This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
label	TABLE 1
caption	Patient characteristics of patients with COVID‐19 associated invasive pulmonary aspergillosis
p	Patient characteristics of patients with COVID‐19 associated invasive pulmonary aspergillosis
table	Characteristics Patient #1 Patient #2 Patient #3 Patient #4 Patient #5 Gender Female Male Male Male Female Age (y) 62 70 54 73 54 Medical history Lap. cholecystectomy for cholecystitis Arterial hypertension Obesity with sleep apnea (BMI 31.5) Hypercholesterolemia Ex‐smoker (30 PY; 5 y previously) Moderate COPD (GOLD 2) Vertebral disc prolapse left L4/5, flavectomy and nucleotomy Ex‐smoker (4 months previously) Arterial hypertension Diabetes mellitus Aneurysm coiling right A. vertebralis Arterial hypertension Bullous Emphysema Smoker Severe COPD (GOLD 3) Previous Hepatitis B No Underlying immuno‐compromising condition (inhalational steroids for COPD) No (intravenous corticosteroid therapy 0.4 mg/kg/d, total of 13 d) (inhalational steroids for COPD) No ICU Ward MICU MICU SICU SICU MICU ARDS Horowitz‐Index, admission 12 Severe (53 mm Hg) Severe (93 mm Hg) Moderate (128 mm Hg) Severe (83 mm Hg) Moderate (167 mm Hg) Prone positioning Yes Yes Yes Yes Yes vvECMO Yes No No No No Acute renal failure Yes Yes Yes Yes Yes Dialysis No SLEDD SLEDD SLEDD No Microbiology Serum GM (>0.5) Negative Positive (0.7) Negative Negative 2× positive (2.7 and 1.3) Fungal culture BALF: Aspergillus fumigatus BALF: negative TA: Aspergillus fumigatus TA: Aspergillus fumigatus TA: negative Susceptibility testing Azole susceptible a Not applicable Azole susceptible Itraconazole MIC 0.380 (mg/L) Voriconazole MIC 0.094 (mg/L) Azole susceptible Itraconazole MIC 0.380 (mg/L) Voriconazole MIC 0.094 (mg/L) Not applicable Fungal PCR BALF: Aspergillus fumigatus BALF: Aspergillus fumigatus BALF: Aspergillus fumigatus TA: Aspergillus fumigatus TA: negative TA/BALF GM (>0.5) BALF: Positive (>2.5) BALF: Positive (>2.5) BALF: Positive (>2.5) Not available Not available Definition of IPA EORTC/MSG Criteria 8 Not classifiable (no host criterion) Not classifiable (no host criterion) Not classifiable (no host criterion) Not classifiable (no host criterion) Not classifiable (no host criterion) (modified) AspICU algorithm 3 , 7 Putative Modified putative 3 (GM positivity) Putative Putative Modified putative 3 (GM positivity) Virology PCR TA: positive for hMPV and SARS‐CoV‐2 (E‐gene: C t 13.29; S‐gene: C t 12.61) TA: positive for hMPV and SARS‐CoV‐2(E‐gene: C t 34.29; ORF1 a/b: C t 31.47) TA positive for SARS‐CoV‐2 (E‐gene: C t 29.74; ORF1 a/b: C t 27.86) TA positive for SARS‐CoV‐2 (E‐gene: C t 21.47; ORF1 a/b: C t 20.12) TA positive for SARS‐CoV‐2 (C t values not available) CT imaging studies Combined bilateral ground‐glass opacities with crazy paving and peripheral nodular consolidations (Video S1, Figure 1A) Ground‐glass opacities with occasional nodules (Video S2, Figure 1B) Bilateral ground‐glass opacities, nodular infiltrates with cavities and air crescent sign (Video S3, Figure 1C) Ground‐glass opacities with occasional nodules, known bullous emphysema (Video S4, Figure 1D) Ground‐glass opacities, smaller areas with crazy paving pattern, central and peripheral consolidations, and smaller nodular infiltrates (Video S5, Figure 1E) Therapy Antifungal treatment Voriconazole iv (6/4 mg/kg BW twice daily) Isavuconazole iv (200 mg thrice daily for 2 d; 200 mg once daily from 3 d) Caspofungin (70/50 mg once daily) followed by voriconazole iv (6/4 mg/kg BW twice daily) Voriconazole iv (6/4 mg/kg BW twice daily) Caspofungin (70/50 mg once daily) followed by voriconazole iv (6/4 mg/kg BW twice daily) Antiviral therapy Supportive only Supportive only Hydroxychloroquine, darunavir and cobicistat at external hospital, in house changed to supportive only Supportive only Ribavirin, lopinavir/ritonavir at external hospital, in house changed to supportive only Outcome Died Died Alive Died Alive
tr	Characteristics Patient #1 Patient #2 Patient #3 Patient #4 Patient #5
th	Characteristics
th	Patient #1
th	Patient #2
th	Patient #3
th	Patient #4
th	Patient #5
tr	Gender Female Male Male Male Female
td	Gender
td	Female
td	Male
td	Male
td	Male
td	Female
tr	Age (y) 62 70 54 73 54
td	Age (y)
td	62
td	70
td	54
td	73
td	54
tr	Medical history Lap. cholecystectomy for cholecystitis Arterial hypertension Obesity with sleep apnea (BMI 31.5) Hypercholesterolemia Ex‐smoker (30 PY; 5 y previously) Moderate COPD (GOLD 2) Vertebral disc prolapse left L4/5, flavectomy and nucleotomy Ex‐smoker (4 months previously) Arterial hypertension Diabetes mellitus Aneurysm coiling right A. vertebralis Arterial hypertension Bullous Emphysema Smoker Severe COPD (GOLD 3) Previous Hepatitis B No
td	Medical history
td	Lap. cholecystectomy for cholecystitis Arterial hypertension Obesity with sleep apnea (BMI 31.5) Hypercholesterolemia Ex‐smoker (30 PY; 5 y previously) Moderate COPD (GOLD 2)
p	Lap. cholecystectomy for cholecystitis
p	Arterial hypertension
p	Obesity with sleep apnea (BMI 31.5)
p	Hypercholesterolemia
p	Ex‐smoker (30 PY; 5 y previously)
p	Moderate COPD (GOLD 2)
td	Vertebral disc prolapse left L4/5, flavectomy and nucleotomy Ex‐smoker (4 months previously)
p	Vertebral disc prolapse left L4/5, flavectomy and nucleotomy
p	Ex‐smoker (4 months previously)
td	Arterial hypertension Diabetes mellitus Aneurysm coiling right A. vertebralis
p	Arterial hypertension
p	Diabetes mellitus
p	Aneurysm coiling right A. vertebralis
td	Arterial hypertension Bullous Emphysema Smoker Severe COPD (GOLD 3) Previous Hepatitis B
p	Arterial hypertension
p	Bullous Emphysema
p	Smoker
p	Severe COPD (GOLD 3)
p	Previous Hepatitis B
td	No
tr	Underlying immuno‐compromising condition (inhalational steroids for COPD) No (intravenous corticosteroid therapy 0.4 mg/kg/d, total of 13 d) (inhalational steroids for COPD) No
td	Underlying immuno‐compromising condition
td	(inhalational steroids for COPD)
td	No
td	(intravenous corticosteroid therapy 0.4 mg/kg/d, total of 13 d)
td	(inhalational steroids for COPD)
td	No
tr	ICU Ward MICU MICU SICU SICU MICU
td	ICU Ward
td	MICU
td	MICU
td	SICU
td	SICU
td	MICU
tr	ARDS
td	ARDS
tr	Horowitz‐Index, admission 12 Severe (53 mm Hg) Severe (93 mm Hg) Moderate (128 mm Hg) Severe (83 mm Hg) Moderate (167 mm Hg)
td	Horowitz‐Index, admission 12
td	Severe (53 mm Hg)
td	Severe (93 mm Hg)
td	Moderate (128 mm Hg)
td	Severe (83 mm Hg)
td	Moderate (167 mm Hg)
tr	Prone positioning Yes Yes Yes Yes Yes
td	Prone positioning
td	Yes
td	Yes
td	Yes
td	Yes
td	Yes
tr	vvECMO Yes No No No No
td	vvECMO
td	Yes
td	No
td	No
td	No
td	No
tr	Acute renal failure Yes Yes Yes Yes Yes
td	Acute renal failure
td	Yes
td	Yes
td	Yes
td	Yes
td	Yes
tr	Dialysis No SLEDD SLEDD SLEDD No
td	Dialysis
td	No
td	SLEDD
td	SLEDD
td	SLEDD
td	No
tr	Microbiology
td	Microbiology
tr	Serum GM (>0.5) Negative Positive (0.7) Negative Negative 2× positive (2.7 and 1.3)
td	Serum GM (>0.5)
td	Negative
td	Positive (0.7)
td	Negative
td	Negative
td	2× positive (2.7 and 1.3)
tr	Fungal culture BALF: Aspergillus fumigatus BALF: negative TA: Aspergillus fumigatus TA: Aspergillus fumigatus TA: negative
td	Fungal culture
td	BALF: Aspergillus fumigatus
td	BALF: negative
td	TA: Aspergillus fumigatus
td	TA: Aspergillus fumigatus
td	TA: negative
tr	Susceptibility testing Azole susceptible a Not applicable Azole susceptible Itraconazole MIC 0.380 (mg/L) Voriconazole MIC 0.094 (mg/L) Azole susceptible Itraconazole MIC 0.380 (mg/L) Voriconazole MIC 0.094 (mg/L) Not applicable
td	Susceptibility testing
td	Azole susceptible a
td	Not applicable
td	Azole susceptible Itraconazole MIC 0.380 (mg/L) Voriconazole MIC 0.094 (mg/L)
p	Azole susceptible
p	Itraconazole MIC 0.380 (mg/L)
p	Voriconazole MIC 0.094 (mg/L)
td	Azole susceptible Itraconazole MIC 0.380 (mg/L) Voriconazole MIC 0.094 (mg/L)
p	Azole susceptible
p	Itraconazole MIC 0.380 (mg/L)
p	Voriconazole MIC 0.094 (mg/L)
td	Not applicable
tr	Fungal PCR BALF: Aspergillus fumigatus BALF: Aspergillus fumigatus BALF: Aspergillus fumigatus TA: Aspergillus fumigatus TA: negative
td	Fungal PCR
td	BALF: Aspergillus fumigatus
td	BALF: Aspergillus fumigatus
td	BALF: Aspergillus fumigatus
td	TA: Aspergillus fumigatus
td	TA: negative
tr	TA/BALF GM (>0.5) BALF: Positive (>2.5) BALF: Positive (>2.5) BALF: Positive (>2.5) Not available Not available
td	TA/BALF GM (>0.5)
td	BALF: Positive (>2.5)
td	BALF: Positive (>2.5)
td	BALF: Positive (>2.5)
td	Not available
td	Not available
tr	Definition of IPA
td	Definition of IPA
tr	EORTC/MSG Criteria 8 Not classifiable (no host criterion) Not classifiable (no host criterion) Not classifiable (no host criterion) Not classifiable (no host criterion) Not classifiable (no host criterion)
td	EORTC/MSG Criteria 8
td	Not classifiable (no host criterion)
td	Not classifiable (no host criterion)
td	Not classifiable (no host criterion)
td	Not classifiable (no host criterion)
td	Not classifiable (no host criterion)
tr	(modified) AspICU algorithm 3 , 7 Putative Modified putative 3 (GM positivity) Putative Putative Modified putative 3 (GM positivity)
td	(modified) AspICU algorithm 3 , 7
td	Putative
td	Modified putative 3 (GM positivity)
td	Putative
td	Putative
td	Modified putative 3 (GM positivity)
tr	Virology
td	Virology
tr	PCR TA: positive for hMPV and SARS‐CoV‐2 (E‐gene: C t 13.29; S‐gene: C t 12.61) TA: positive for hMPV and SARS‐CoV‐2(E‐gene: C t 34.29; ORF1 a/b: C t 31.47) TA positive for SARS‐CoV‐2 (E‐gene: C t 29.74; ORF1 a/b: C t 27.86) TA positive for SARS‐CoV‐2 (E‐gene: C t 21.47; ORF1 a/b: C t 20.12) TA positive for SARS‐CoV‐2 (C t values not available)
td	PCR
td	TA: positive for hMPV and SARS‐CoV‐2 (E‐gene: C t 13.29; S‐gene: C t 12.61)
td	TA: positive for hMPV and SARS‐CoV‐2(E‐gene: C t 34.29; ORF1 a/b: C t 31.47)
td	TA positive for SARS‐CoV‐2 (E‐gene: C t 29.74; ORF1 a/b: C t 27.86)
td	TA positive for SARS‐CoV‐2 (E‐gene: C t 21.47; ORF1 a/b: C t 20.12)
td	TA positive for SARS‐CoV‐2 (C t values not available)
tr	CT imaging studies Combined bilateral ground‐glass opacities with crazy paving and peripheral nodular consolidations (Video S1, Figure 1A) Ground‐glass opacities with occasional nodules (Video S2, Figure 1B) Bilateral ground‐glass opacities, nodular infiltrates with cavities and air crescent sign (Video S3, Figure 1C) Ground‐glass opacities with occasional nodules, known bullous emphysema (Video S4, Figure 1D) Ground‐glass opacities, smaller areas with crazy paving pattern, central and peripheral consolidations, and smaller nodular infiltrates (Video S5, Figure 1E)
td	CT imaging studies
td	Combined bilateral ground‐glass opacities with crazy paving and peripheral nodular consolidations (Video S1, Figure 1A)
td	Ground‐glass opacities with occasional nodules (Video S2, Figure 1B)
td	Bilateral ground‐glass opacities, nodular infiltrates with cavities and air crescent sign (Video S3, Figure 1C)
td	Ground‐glass opacities with occasional nodules, known bullous emphysema (Video S4, Figure 1D)
td	Ground‐glass opacities, smaller areas with crazy paving pattern, central and peripheral consolidations, and smaller nodular infiltrates (Video S5, Figure 1E)
tr	Therapy
td	Therapy
tr	Antifungal treatment Voriconazole iv (6/4 mg/kg BW twice daily) Isavuconazole iv (200 mg thrice daily for 2 d; 200 mg once daily from 3 d) Caspofungin (70/50 mg once daily) followed by voriconazole iv (6/4 mg/kg BW twice daily) Voriconazole iv (6/4 mg/kg BW twice daily) Caspofungin (70/50 mg once daily) followed by voriconazole iv (6/4 mg/kg BW twice daily)
td	Antifungal treatment
td	Voriconazole iv (6/4 mg/kg BW twice daily)
td	Isavuconazole iv (200 mg thrice daily for 2 d; 200 mg once daily from 3 d)
td	Caspofungin (70/50 mg once daily) followed by voriconazole iv (6/4 mg/kg BW twice daily)
td	Voriconazole iv (6/4 mg/kg BW twice daily)
td	Caspofungin (70/50 mg once daily) followed by voriconazole iv (6/4 mg/kg BW twice daily)
tr	Antiviral therapy Supportive only Supportive only Hydroxychloroquine, darunavir and cobicistat at external hospital, in house changed to supportive only Supportive only Ribavirin, lopinavir/ritonavir at external hospital, in house changed to supportive only
td	Antiviral therapy
td	Supportive only
td	Supportive only
td	Hydroxychloroquine, darunavir and cobicistat at external hospital, in house changed to supportive only
td	Supportive only
td	Ribavirin, lopinavir/ritonavir at external hospital, in house changed to supportive only
tr	Outcome Died Died Alive Died Alive
td	Outcome
td	Died
td	Died
td	Alive
td	Died
td	Alive
table-wrap-foot	Abbreviations: ARDS, acute respiratory distress syndrome; BALF, bronchoalveolar lavage fluid; BW, body weight; COPD, chronic obstructive pulmonary disease; C t, threshold cycle; EORTC/MSG, European Organization for Research and Treatment of Cancer/Mycoses Study Group; GOLD, global initiative for chronic obstructive lung disease; hMPV, human metapneumovirus; IPA, invasive pulmonary aspergillosis; kg, kilogram; lap, laparoscopic; LVB, lumbar vertebral body; mg, milligram; MIC, minimal inhibitory concentration; MICU, medical ICU; ORF, open reading frame; PCR, polymerase chain reaction; PY, pack‐year history; SICU, surgical ICU; SLEDD, slow low‐efficient daily dialysis; TA, tracheal aspirate; vvECMO, veno‐venous extracorporeal membrane oxygenation. a Antifungal susceptibility testing by VIPcheck™. 6
footnote	Abbreviations: ARDS, acute respiratory distress syndrome; BALF, bronchoalveolar lavage fluid; BW, body weight; COPD, chronic obstructive pulmonary disease; C t, threshold cycle; EORTC/MSG, European Organization for Research and Treatment of Cancer/Mycoses Study Group; GOLD, global initiative for chronic obstructive lung disease; hMPV, human metapneumovirus; IPA, invasive pulmonary aspergillosis; kg, kilogram; lap, laparoscopic; LVB, lumbar vertebral body; mg, milligram; MIC, minimal inhibitory concentration; MICU, medical ICU; ORF, open reading frame; PCR, polymerase chain reaction; PY, pack‐year history; SICU, surgical ICU; SLEDD, slow low‐efficient daily dialysis; TA, tracheal aspirate; vvECMO, veno‐venous extracorporeal membrane oxygenation.
p	Abbreviations: ARDS, acute respiratory distress syndrome; BALF, bronchoalveolar lavage fluid; BW, body weight; COPD, chronic obstructive pulmonary disease; C t, threshold cycle; EORTC/MSG, European Organization for Research and Treatment of Cancer/Mycoses Study Group; GOLD, global initiative for chronic obstructive lung disease; hMPV, human metapneumovirus; IPA, invasive pulmonary aspergillosis; kg, kilogram; lap, laparoscopic; LVB, lumbar vertebral body; mg, milligram; MIC, minimal inhibitory concentration; MICU, medical ICU; ORF, open reading frame; PCR, polymerase chain reaction; PY, pack‐year history; SICU, surgical ICU; SLEDD, slow low‐efficient daily dialysis; TA, tracheal aspirate; vvECMO, veno‐venous extracorporeal membrane oxygenation.
footnote	a Antifungal susceptibility testing by VIPcheck™. 6
label	a
p	Antifungal susceptibility testing by VIPcheck™. 6
p	For patient #1 SARS‐CoV‐2 RT‐PCR Kit (altona Diagnostics) and for patients #2, #3 and #4 cobas® SARS‐CoV‐2 Test (Roche) were used. For patient #5, kit manufacturer remains unknown. Respective C t values are given in Table 1 where available. hMPV‐PCR was performed with NxTAG® Respiratory Pathogen Panel (Luminex). Aspergillus 28S rDNA‐Realtime PCR was performed as in‐house PCR test for screening purposes. Species identification was performed by artus® Aspergillus diff. RG PCR kit (Qiagen). For galactomannan testing from serum, bronchoalveolar lavage fluid (BALF) or tracheal aspirate (TA) Platelia Aspergillus antigen ELISA (Bio‐Rad Laboratories) was used. Antifungal susceptibility testing was performed using concentration gradient strips on RPMI agar plates. In brief, spore suspensions of the fungal isolates were adjusted to 106 CFU/mL and inoculated with MIC test strips for itraconazole and voriconazole (bioMérieux). MICs were determined visually after 48 hours of incubation at 35°C. VIPcheck™ (Mediaproducts BV) was performed in patient #1 for early detection of azole resistance. 6
p	COVID‐19 associated IPA was classified according to the (modified) 3 AspICU algorithm 7 with the addition that positive galactomannan (≥1) from BALF or TA, or two consecutively but separately drawn positive serum samples (≥1) were accepted as entry criterion. 8 Severe SARS‐CoV2 infection with ARDS was accepted as host criterion (acquired immunodeficiency) (Table 1). This study was carried out in accordance with the ethical principles reflected in the Declaration of Helsinki 9 and was approved by the ethic committee of the University Hospital of Cologne (Identifier of the University of Cologne Ethics Committee 20‐1157).
sec	3 RESULTS A 62‐year‐old woman was admitted to our ICU. She was intubated and developed severe ARDS with a Horowitz‐Index of 53 mm Hg. At the contrast‐enhanced CT a combination of emphysema, bilateral ground‐glass opacities with crazy paving and some peripheral nodular consolidations were seen (Video S1, patient #1, Figure 1A). Despite prone positioning, the patient required rescue veno‐venous extracorporeal membrane oxygenation (ECMO). PCR for SARS‐CoV‐2 and human metapneumovirus (hMPV) was positive in BALF. The patient developed severe intrapulmonary bleeding from the right main bronchus, which was stanched by cold lavages and instillation of tranexamic acid. BALF culture grew Aspergillus fumigatus, was positive for galactomannan, and intravenous voriconazole treatment was commenced. FIGURE 1 Chest CT images of patients with COVID‐19 Associated Invasive Pulmonary Aspergillosis. A, Patient #1: Combined bilateral ground‐glass opacities with crazy paving and peripheral nodular consolidations. B, Patient #2: Ground‐glass opacities with small nodular infiltrations of up to 1 cm. C, Patient #3: Bilateral ground‐glass opacities diffuse nodular infiltrates and cystic cavities and partly air crescent sign. D, Patient #4: Bullous emphysema and ground‐glass opacities, interstitial changes and consolidations with nodular infiltrates. E, Patient #5: Ground‐glass opacities, smaller areas with crazy paving pattern, central and peripheral consolidations, and smaller nodular infiltrates A 70‐year‐old man was admitted to the ICU because of ARDS with a Horowitz‐Index of 93 mm Hg. PCR on BALF was tested positive for hMPV, SARS‐CoV‐2 and Aspergillus fumigatus. Two days before, serum galactomannan had turned positive. BALF was tested positive for galactomannan. Chest CT showed ground‐glass opacities with some small nodular infiltrations of up to 1 cm (Video S2, patient #2 Figure 1B). Due to acute renal failure requiring slow low‐efficient daily dialysis (SLEDD) and elevated liver enzymes, intravenous isavuconazole treatment was started. A 54‐year‐old man presented with ARDS with a Horowitz‐Index of 128 mm Hg. TA revealed SARS‐CoV‐2 PCR positive and Aspergillus fumigatus in culture. BALF was positive for galactomannan. Chest CT showed bilateral ground‐glass opacities, diffuse nodular infiltrates and cystic cavities and partly air crescent sign (Video S3, patient #3 Figure 1C). Intravenous voriconazole treatment was initiated. A 73‐year‐old man was transferred to the ICU due to ARDS with PCR on TA tested positive for SARS‐CoV‐2, and Aspergillus fumigatus that also grew in culture. Chest CT showed known bullous emphysema with ground‐glass opacities and consolidations with nodular infiltrates (Video S4, patient #4, Figure 1D). Intravenous voriconazole was begun. A 54‐year‐old woman was transferred to the ICU due to ARDS with PCR on TA tested positive for SARS‐CoV‐2. Serum galactomannan returned positive in two consecutive serum samples. Chest CT showed bilateral ground‐glass opacities, smaller areas with crazy paving pattern, central and peripheral consolidations, and smaller nodular infiltrates (Video S5, patient #5, Figure 1E). Intravenous caspofungin was started. No autopsies were performed. Detailed patient characteristics are given in Table 1.
label	3
title	RESULTS
p	A 62‐year‐old woman was admitted to our ICU. She was intubated and developed severe ARDS with a Horowitz‐Index of 53 mm Hg. At the contrast‐enhanced CT a combination of emphysema, bilateral ground‐glass opacities with crazy paving and some peripheral nodular consolidations were seen (Video S1, patient #1, Figure 1A). Despite prone positioning, the patient required rescue veno‐venous extracorporeal membrane oxygenation (ECMO). PCR for SARS‐CoV‐2 and human metapneumovirus (hMPV) was positive in BALF. The patient developed severe intrapulmonary bleeding from the right main bronchus, which was stanched by cold lavages and instillation of tranexamic acid. BALF culture grew Aspergillus fumigatus, was positive for galactomannan, and intravenous voriconazole treatment was commenced.
figure	FIGURE 1 Chest CT images of patients with COVID‐19 Associated Invasive Pulmonary Aspergillosis. A, Patient #1: Combined bilateral ground‐glass opacities with crazy paving and peripheral nodular consolidations. B, Patient #2: Ground‐glass opacities with small nodular infiltrations of up to 1 cm. C, Patient #3: Bilateral ground‐glass opacities diffuse nodular infiltrates and cystic cavities and partly air crescent sign. D, Patient #4: Bullous emphysema and ground‐glass opacities, interstitial changes and consolidations with nodular infiltrates. E, Patient #5: Ground‐glass opacities, smaller areas with crazy paving pattern, central and peripheral consolidations, and smaller nodular infiltrates
label	FIGURE 1
caption	Chest CT images of patients with COVID‐19 Associated Invasive Pulmonary Aspergillosis. A, Patient #1: Combined bilateral ground‐glass opacities with crazy paving and peripheral nodular consolidations. B, Patient #2: Ground‐glass opacities with small nodular infiltrations of up to 1 cm. C, Patient #3: Bilateral ground‐glass opacities diffuse nodular infiltrates and cystic cavities and partly air crescent sign. D, Patient #4: Bullous emphysema and ground‐glass opacities, interstitial changes and consolidations with nodular infiltrates. E, Patient #5: Ground‐glass opacities, smaller areas with crazy paving pattern, central and peripheral consolidations, and smaller nodular infiltrates
p	Chest CT images of patients with COVID‐19 Associated Invasive Pulmonary Aspergillosis. A, Patient #1: Combined bilateral ground‐glass opacities with crazy paving and peripheral nodular consolidations. B, Patient #2: Ground‐glass opacities with small nodular infiltrations of up to 1 cm. C, Patient #3: Bilateral ground‐glass opacities diffuse nodular infiltrates and cystic cavities and partly air crescent sign. D, Patient #4: Bullous emphysema and ground‐glass opacities, interstitial changes and consolidations with nodular infiltrates. E, Patient #5: Ground‐glass opacities, smaller areas with crazy paving pattern, central and peripheral consolidations, and smaller nodular infiltrates
p	A 70‐year‐old man was admitted to the ICU because of ARDS with a Horowitz‐Index of 93 mm Hg. PCR on BALF was tested positive for hMPV, SARS‐CoV‐2 and Aspergillus fumigatus. Two days before, serum galactomannan had turned positive. BALF was tested positive for galactomannan. Chest CT showed ground‐glass opacities with some small nodular infiltrations of up to 1 cm (Video S2, patient #2 Figure 1B). Due to acute renal failure requiring slow low‐efficient daily dialysis (SLEDD) and elevated liver enzymes, intravenous isavuconazole treatment was started.
p	A 54‐year‐old man presented with ARDS with a Horowitz‐Index of 128 mm Hg. TA revealed SARS‐CoV‐2 PCR positive and Aspergillus fumigatus in culture. BALF was positive for galactomannan. Chest CT showed bilateral ground‐glass opacities, diffuse nodular infiltrates and cystic cavities and partly air crescent sign (Video S3, patient #3 Figure 1C). Intravenous voriconazole treatment was initiated.
p	A 73‐year‐old man was transferred to the ICU due to ARDS with PCR on TA tested positive for SARS‐CoV‐2, and Aspergillus fumigatus that also grew in culture. Chest CT showed known bullous emphysema with ground‐glass opacities and consolidations with nodular infiltrates (Video S4, patient #4, Figure 1D). Intravenous voriconazole was begun.
p	A 54‐year‐old woman was transferred to the ICU due to ARDS with PCR on TA tested positive for SARS‐CoV‐2. Serum galactomannan returned positive in two consecutive serum samples. Chest CT showed bilateral ground‐glass opacities, smaller areas with crazy paving pattern, central and peripheral consolidations, and smaller nodular infiltrates (Video S5, patient #5, Figure 1E). Intravenous caspofungin was started. No autopsies were performed. Detailed patient characteristics are given in Table 1.
sec	4 DISCUSSION Patients with ARDS triggered by viral infection, in particular influenza, are prone to invasive aspergillosis even in absence of prior immunodeficiency. 2 , 3 We report putative IPA in five of 19 COVID‐19 patients with moderate to severe ARDS without underlying immunocompromising disease on two separate ICUs. Spontaneous intrapulmonary bleeding and haemoptysis are typical complications of IPA. Ground‐glass opacities characterise COVID‐19 as well as IPA, thus comprehensive microbiological evaluation can prevent missing IPA. By applying strict interpretation of the host and risk factors for invasive aspergillosis according to the European Organization for Research and Treatment of Cancer/Mycoses Study Group definitions the risk of missed diagnosis increases in the COVID‐19 population. 8 However, a most complicated issue in ARDS patients is to differentiate Aspergillus colonisation from invasive disease—especially as radiological imaging is non‐specific. To address this issue, a consensus project will seek to provide standard definitions for invasive fungal disease in critically ill adult patients. 10 Our observations suggest increased risk for critically ill COVID‐19 patients to develop co‐infection with Aspergillus, which is likely to increase mortality rates further. Therefore, testing for the presence of Aspergillus in lower respiratory secretions and galactomannan in consecutive serum samples in COVID‐19 ICU patients should be considered. 11 Our findings need to be confirmed in clinical trials to elucidate the role of potential IPA after COVID‐19. With this report, we aim to call attention to the critical phenomenon of COVID‐19 associated IA in ARDS patients.
label	4
title	DISCUSSION
p	Patients with ARDS triggered by viral infection, in particular influenza, are prone to invasive aspergillosis even in absence of prior immunodeficiency. 2 , 3 We report putative IPA in five of 19 COVID‐19 patients with moderate to severe ARDS without underlying immunocompromising disease on two separate ICUs.
p	Spontaneous intrapulmonary bleeding and haemoptysis are typical complications of IPA. Ground‐glass opacities characterise COVID‐19 as well as IPA, thus comprehensive microbiological evaluation can prevent missing IPA.
p	By applying strict interpretation of the host and risk factors for invasive aspergillosis according to the European Organization for Research and Treatment of Cancer/Mycoses Study Group definitions the risk of missed diagnosis increases in the COVID‐19 population. 8 However, a most complicated issue in ARDS patients is to differentiate Aspergillus colonisation from invasive disease—especially as radiological imaging is non‐specific. To address this issue, a consensus project will seek to provide standard definitions for invasive fungal disease in critically ill adult patients. 10
p	Our observations suggest increased risk for critically ill COVID‐19 patients to develop co‐infection with Aspergillus, which is likely to increase mortality rates further. Therefore, testing for the presence of Aspergillus in lower respiratory secretions and galactomannan in consecutive serum samples in COVID‐19 ICU patients should be considered. 11
p	Our findings need to be confirmed in clinical trials to elucidate the role of potential IPA after COVID‐19. With this report, we aim to call attention to the critical phenomenon of COVID‐19 associated IA in ARDS patients.
sec	CONFLICT OF INTEREST PK has received non‐financial scientific grants from Miltenyi Biotec GmbH, Bergisch Gladbach, Germany, and the Cologne Excellence Cluster on Cellular Stress Responses in Aging‐Associated Diseases, University of Cologne, Cologne, Germany, and received lecture honoraria from Akademie für Infektionsmedizin e.V., Astellas Pharma, Gilead Sciences, GPR Academy Ruesselsheim, MSD Sharp & Dohme GmbH, and University Hospital, LMU Munich outside the submitted work. OAC is supported by the German Federal Ministry of Research and Education, is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy—CECAD, EXC 2030—390 661 388 and has received research grants from, is an advisor to, or received lecture honoraria from Actelion, Allecra Therapeutics, Amplyx, Astellas, Basilea, Biosys UK Limited, Cidara, Da Volterra, Entasis, F2G, Gilead, Grupo Biotoscana, Janssen Pharmaceuticals, Matinas, Medicines Company, MedPace, Melinta Therapeutics, Menarini Ricerche, Roche Diagnostics, Merck/MSD, Nabriva Therapeutics, Octapharma, Paratek Pharmaceuticals, Pfizer, PSI, Rempex, Scynexis, Seres Therapeutics, Tetraphase, Vical. BWB is European Resuscitation Council (ERC) Board Director Science and Research; Chairman of the German Resuscitation Council (GRC); Member of the Advanced Life Support (ALS) Task Force of the International Liaison Committee on Resuscitation (ILCOR); Member of the executive committee of the German Interdisciplinary Association for Intensive and Emergency Medicine (DIVI); Associated Editor of the European Journal of Anaesthesiology (EJA), Co‐Editor of ‘Resuscitation’; Editor of the Journal ‘Notfall + Rettungsmedizin’. He received professional fees for lectures from the following companies: Medupdate GmbH, ‘Forum für medizinische Fortbildung (FomF)’, Baxalta Deutschland GmbH, Bayer Vital GmbH, ZOLL Medical Deutschland GmbH, C. R. Bard GmbH, GS Elektromedizinische Geräte G. Stemple GmbH, Novartis Pharma GmbH, Philips GmbH Market DACH. FD reports personal fees from Forum für medizinische Fortbildung GmbH, BioMérieux GmBH, M3 Inc, and pm‐result GmbH, outside the submitted work. FD: Associated Editor of 'BMC Anesthesiology'. DAE has no potential conflict of interest. FF reports scientific grants from the Medical Faculty of the University of Cologne (Maria Pesch grant and GEROK grant), outside the submitted work. MH reports grants from Roche, personal fees from Roche, personal fees from Roche, grants from Abbvie, personal fees from Abbvie, personal fees from Abbvie, during the conduct of the study; grants from Gilead, personal fees from Gilead, personal fees from Gilead, grants from Janssen, personal fees from Janssen, personal fees from Janssen, personal fees from Celgene, personal fees from Celgene, personal fees from Boehringer Ingelheim, personal fees from Boehringer Ingelheim, outside the submitted work. NJ reports lecture fees from Gilead, Infectopharm and MSD and travel grants from Gilead, Basilea, Correvio and Pfizer outside the submitted work. FK is supported by the German Center for Infection Research (DZIF), the German Research Foundation (CRC 1279 and CRC 1310), the Bill and Melinda Gates Foundation, and the European Research Council (ERC‐StG639961). FK received lecture and consulting honoraria from MSD, Roche and ViiV outside the submitted work. TP has no potential conflict of interest. JR has nothing to disclose. MK reports personal fees from Pfizer, Astellas Pharma, Gilead Sciences and MSD Sharp & Dohme GmbH outside the submitted work. BB is a consultant to Baxalta, Celgene, MSD, Mundipharma and received Honoraria and Research funding from Astellas, Celgene, J&J, Maquet, Miltenyi, MSD, Takeda, Roche and Sanofi. ASV reports travel grants from Gilead Sciences outside the submitted work.
title	CONFLICT OF INTEREST
p	PK has received non‐financial scientific grants from Miltenyi Biotec GmbH, Bergisch Gladbach, Germany, and the Cologne Excellence Cluster on Cellular Stress Responses in Aging‐Associated Diseases, University of Cologne, Cologne, Germany, and received lecture honoraria from Akademie für Infektionsmedizin e.V., Astellas Pharma, Gilead Sciences, GPR Academy Ruesselsheim, MSD Sharp & Dohme GmbH, and University Hospital, LMU Munich outside the submitted work. OAC is supported by the German Federal Ministry of Research and Education, is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy—CECAD, EXC 2030—390 661 388 and has received research grants from, is an advisor to, or received lecture honoraria from Actelion, Allecra Therapeutics, Amplyx, Astellas, Basilea, Biosys UK Limited, Cidara, Da Volterra, Entasis, F2G, Gilead, Grupo Biotoscana, Janssen Pharmaceuticals, Matinas, Medicines Company, MedPace, Melinta Therapeutics, Menarini Ricerche, Roche Diagnostics, Merck/MSD, Nabriva Therapeutics, Octapharma, Paratek Pharmaceuticals, Pfizer, PSI, Rempex, Scynexis, Seres Therapeutics, Tetraphase, Vical. BWB is European Resuscitation Council (ERC) Board Director Science and Research; Chairman of the German Resuscitation Council (GRC); Member of the Advanced Life Support (ALS) Task Force of the International Liaison Committee on Resuscitation (ILCOR); Member of the executive committee of the German Interdisciplinary Association for Intensive and Emergency Medicine (DIVI); Associated Editor of the European Journal of Anaesthesiology (EJA), Co‐Editor of ‘Resuscitation’; Editor of the Journal ‘Notfall + Rettungsmedizin’. He received professional fees for lectures from the following companies: Medupdate GmbH, ‘Forum für medizinische Fortbildung (FomF)’, Baxalta Deutschland GmbH, Bayer Vital GmbH, ZOLL Medical Deutschland GmbH, C. R. Bard GmbH, GS Elektromedizinische Geräte G. Stemple GmbH, Novartis Pharma GmbH, Philips GmbH Market DACH. FD reports personal fees from Forum für medizinische Fortbildung GmbH, BioMérieux GmBH, M3 Inc, and pm‐result GmbH, outside the submitted work. FD: Associated Editor of 'BMC Anesthesiology'. DAE has no potential conflict of interest. FF reports scientific grants from the Medical Faculty of the University of Cologne (Maria Pesch grant and GEROK grant), outside the submitted work. MH reports grants from Roche, personal fees from Roche, personal fees from Roche, grants from Abbvie, personal fees from Abbvie, personal fees from Abbvie, during the conduct of the study; grants from Gilead, personal fees from Gilead, personal fees from Gilead, grants from Janssen, personal fees from Janssen, personal fees from Janssen, personal fees from Celgene, personal fees from Celgene, personal fees from Boehringer Ingelheim, personal fees from Boehringer Ingelheim, outside the submitted work. NJ reports lecture fees from Gilead, Infectopharm and MSD and travel grants from Gilead, Basilea, Correvio and Pfizer outside the submitted work. FK is supported by the German Center for Infection Research (DZIF), the German Research Foundation (CRC 1279 and CRC 1310), the Bill and Melinda Gates Foundation, and the European Research Council (ERC‐StG639961). FK received lecture and consulting honoraria from MSD, Roche and ViiV outside the submitted work. TP has no potential conflict of interest. JR has nothing to disclose. MK reports personal fees from Pfizer, Astellas Pharma, Gilead Sciences and MSD Sharp & Dohme GmbH outside the submitted work. BB is a consultant to Baxalta, Celgene, MSD, Mundipharma and received Honoraria and Research funding from Astellas, Celgene, J&J, Maquet, Miltenyi, MSD, Takeda, Roche and Sanofi. ASV reports travel grants from Gilead Sciences outside the submitted work.
sec	AUTHOR CONTRIBUTIONS Philipp Koehler: Conceptualization (lead); Investigation (lead); Writing‐original draft (lead); Writing‐review & editing (lead). Oliver A. Cornely: Conceptualization (lead); Investigation (lead); Writing‐original draft (lead); Writing‐review & editing (lead). Bernd W. Böttiger: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Fabian Dusse: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Dennis A. Eichenauer: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Frieder Fuchs: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Michael Hallek: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Norma Jung: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Florian Klein: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Thorsten Persigehl: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Jan Rybniker: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Matthias Kochanek: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Boris Böll: Investigation (lead); Writing‐original draft (lead); Writing‐review & editing (lead). Alexander Shimabukuro‐Vornhagen: Investigation (lead); Writing‐original draft (lead); Writing‐review & editing (lead).
title	AUTHOR CONTRIBUTIONS
p	Philipp Koehler: Conceptualization (lead); Investigation (lead); Writing‐original draft (lead); Writing‐review & editing (lead). Oliver A. Cornely: Conceptualization (lead); Investigation (lead); Writing‐original draft (lead); Writing‐review & editing (lead). Bernd W. Böttiger: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Fabian Dusse: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Dennis A. Eichenauer: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Frieder Fuchs: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Michael Hallek: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Norma Jung: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Florian Klein: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Thorsten Persigehl: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Jan Rybniker: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Matthias Kochanek: Investigation (supporting); Writing‐original draft (supporting); Writing‐review & editing (supporting). Boris Böll: Investigation (lead); Writing‐original draft (lead); Writing‐review & editing (lead). Alexander Shimabukuro‐Vornhagen: Investigation (lead); Writing‐original draft (lead); Writing‐review & editing (lead).
sec	ETHICAL APPROVAL The authors confirm that the ethical policies of the journal, as noted in the author's guideline page, have been adhered to. Our study was approved by the ethic committee of the University Hospital of Cologne (Identifier of the University of Cologne Ethics Committee 20‐1157).
title	ETHICAL APPROVAL
p	The authors confirm that the ethical policies of the journal, as noted in the author's guideline page, have been adhered to. Our study was approved by the ethic committee of the University Hospital of Cologne (Identifier of the University of Cologne Ethics Committee 20‐1157).
sec	Supporting information Video S1 Click here for additional data file. Video S2 Click here for additional data file. Video S3 Click here for additional data file. Video S4 Click here for additional data file. Video S5 Click here for additional data file. Supplementary Material Click here for additional data file.
title	Supporting information
caption	Video S1
p	Video S1
caption	Click here for additional data file.
p	Click here for additional data file.
caption	Video S2
p	Video S2
caption	Click here for additional data file.
p	Click here for additional data file.
caption	Video S3
p	Video S3
caption	Click here for additional data file.
p	Click here for additional data file.
caption	Video S4
p	Video S4
caption	Click here for additional data file.
p	Click here for additional data file.
caption	Video S5
p	Video S5
caption	Click here for additional data file.
p	Click here for additional data file.
caption	Supplementary Material
p	Supplementary Material
caption	Click here for additional data file.
p	Click here for additional data file.
back	ACKNOWLEDGMENT The authors thank Susann Blossfeld for technical assistance.
ack	ACKNOWLEDGMENT The authors thank Susann Blossfeld for technical assistance.
title	ACKNOWLEDGMENT
p	The authors thank Susann Blossfeld for technical assistance.

projects that have annotations to this span

There is no project

TAB JSON ListView MergeView

PMC:7267243 / 20-30 JSONTXT

Document structure show

projects that have annotations to this span

PMC:7267243 / 20-30 JSON TXT